Metabolic syndrome in patients with prostate cancer

Santana, Isabelle; Moura, Gustavo Souza; Vieira, Nivaldo Farias; Cipolotti, Rosana

doi:10.1590/s1516-31802008000500006

Cited by 8 publications

(6 citation statements)

References 25 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In univariate analysis, positive associations with prostate cancer prevalence and hyperglycemia low HDL-cholesterol, as well as elevated WHR, SBP, and DBP have also been observed (de Santana et al, 2008;Coman et al, 2008). A prospective cohort based on 29,364 Norwegian men followed up for prostate cancer incidence and mortality from 1995-1997 to the end of 2005 in the second Nord Trøndelag Health Study (HUNT 2) showed little evidence that baseline BMI, waist circumference, WHR, total or HDL-cholesterol, or triglycerides were associated with incident or fatal prostate cancer.…”

Section: Components Of Metabolic Syndrome and Prostate Cancer Riskmentioning

confidence: 99%

Prostate Cancer and Metabolic Syndrome: Is there a link?

McGrowder¹,

Jackson²,

Crawford³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Metabolic syndrome has become quite prevalent within our society. Over the past two decades, the prevalence of metabolic syndrome has sharply increased worldwide and it has become a major public health problem in several countries. It is associated with the global epidemic of obesity and diabetes mellitus and imposes numerous cardiovascular risks. Prostate cancer is the second most common cancer among men, surpassed only by non-melanoma skin cancer. A considerable body of evidence exists suggesting that some components of the metabolic syndrome have been associated with the risk of prostate cancer. These components include obesity, an abdominal fat distribution, and hyperinsulinemia. Androgen deprivation therapy (ADT) is the most widely used therapeutic modality in prostate cancer. It changed the body composition and lipid profile of men with prostate cancer. Androgen deficiency is associated with increased levels of total cholesterol, low-density lipoprotein (LDL)-cholesterol, increased production of proinflammatory factors, and increased thickness of the arterial wall and contributes to endothelial dysfunction. The aim of this review is to evaluate the association between metabolic syndrome and prostate cancer and to discuss the implications of androgen deficiency in men with cardiovascular risk factors. A comprehensive literature search was carried out with the use of PubMed from 1980 through 2011, and relevant articles pertinent to metabolic syndrome and prostate cancer are evaluated and discussed.

show abstract

Section: Components Of Metabolic Syndrome and Prostate Cancer Riskmentioning

confidence: 99%

Prostate Cancer and Metabolic Syndrome: Is there a link?

McGrowder¹,

Jackson²,

Crawford³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…In a prospective study, Martin et al found that hypertension was associated with an increased risk in developing prostate cancer (RR 1.05, 95%CI 1.01-1.10) (20). A small case-control study in Bra-zil also showed a signifi cantly greater occurrence of arterial hypertension in men with prostate cancer (21). Our fi ndings demonstrated an increased univariate risk of prostate cancer in men with history of increased blood pressure (non-adjusted RR 1.74, 95%CI 1.05-2.89).…”

Section: Discussionmentioning

confidence: 99%

The significance of biological, environmental, and social risk factors for prostate cancer in a cohort study in Brazil

Romero¹,

Romero²,

Almeida³

et al. 2012

Int. braz j urol.

View full text Add to dashboard Cite

Purpose: To evaluate the signifi cance of several risk factors for prostate cancer in a cohort of Brazilian men. Subjects and methods: Men  40 years-old participating in a prostate cancer screening program between December 2006 and April 2011 in the city of Curitiba, Brazil, were evaluated to determine the prevalence, relative risk (RR) and 95% CI of prostate cancer according to age, race, ethnicity, family history of prostate cancer, educational level, and history of vasectomy, increased blood pressure, diabetes mellitus, and urethritis. Results: In 2121 men included in this study, prostate cancer prevalence was 0.6% for men between 40-49 years versus 2.0% (adjusted RR = 2.58), 7.7% (adjusted RR = 5.76), and 8.4% (adjusted RR = 4.88) for men 50-59 years, 60-69 years, and  70 years, respectively (p < 0.05 to all). The prevalence of cancer was 5.1% in blacks versus 3.3% in whites (adjusted RR = 1.56, p > 0.05); 6.1% in African descendants, in comparison to 3.0% in non-African descendants (adjusted RR = 3.17, p < 0.05); 5.1% in men with a positive family history, compared to 2.5% in those with no family history (adjusted RR = 1.55, p > 0.05); and 4.8% in participants with incomplete elementary school level or lower, compared to 2.2% in men with complete elementary school level or higher education (adjusted RR = 1.85, p > 0.05). Men with/without history of vasectomy, increased blood pressure, diabetes, and urethritis had a prostate cancer prevalence of 0.8%/3.0% (adjusted RR = 0.23, p > 0.05), 3.8%/2.2% (adjusted RR = 1.16, p > 0.05), 3.7%/2.6% (adjusted RR = 1.39, p > 0.05), and 2.6%/2.6% (adjusted RR = 0.99, p > 0.05), respectively. Conclusions: Risk factors associated with an increased prevalence of prostate cancer in this cohort included increasing age and African ethnicity.

show abstract

“…Univariate analysis also showed positive associations with PCa prevalence and hyperglycemia (OR, 7.31), low HDL (high-density lipoprotein) cholesterol (OR, 9.93), increased waist-to-hip ratio (WHR), systolic arterial pressure, and diastolic blood pressure heart rate [26]. Another study found that every 12 mm Hg increase in diastolic blood pressure was independently associated with an 8% increase in the incidence of PCa [27].…”

Section: The Influence Of Metabolic Syndrome On the Development Of Pr...mentioning

confidence: 95%

Effect of Metabolic Syndrome in Patients with Prostate Cancer (Review)

Peshkov¹,

Peshkova²,

Reshetov³

2022

Advances in Soft Tissue Tumors

View full text Add to dashboard Cite

The human prostate gland is an endocrine organ in which dysregulation of various hormonal factors plays a key role in the development of non-tissue transformation and leads to the formation of prostate cancer. Existing epidemiological data confirm the role of the components of the metabolic syndrome, namely obesity, hypercholesterolemia, diabetes, and hyperinsulinemia, in the development and/or progression of prostate cancer. Although the exact mechanisms underlying the relationship between metabolic syndrome and prostate cancer remain largely unknown, it has been shown that various “in vitro” and animal experiments with models of the metabolic syndrome contribute to survival, mitogenesis, metastasis, and treatment resistance pathways through various adaptive reactions, such as intracellular steroidogenesis and lipogenesis. Although the exact biopathophysiological mechanisms between metabolic syndrome and prostate cancer have yet to be studied, drugs that target specific components of the metabolic syndrome have also provided evidence for the relationship between metabolic syndrome, its components, and prostate cancer. The appearance of “in vitro” results and molecular genetic research data will bring us closer to using this knowledge to determine specific ways of cancer-specific survival and improve treatment outcomes in patients with this disease.

show abstract

Metabolic syndrome in patients with prostate cancer

Cited by 8 publications

References 25 publications

Prostate Cancer and Metabolic Syndrome: Is there a link?

Prostate Cancer and Metabolic Syndrome: Is there a link?

The significance of biological, environmental, and social risk factors for prostate cancer in a cohort study in Brazil

Effect of Metabolic Syndrome in Patients with Prostate Cancer (Review)

Contact Info

Product

Resources

About